XL092 for advanced thyroid cancer that no longer responds to radioactive iodine
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial is testing a new oral medication, XL092, for people with advanced thyroid cancer that has stopped responding to radioactive iodine therapy. The goal is to see if XL092 can slow or stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of thyroid cancer (papillary, follicular, Hurthle cell, or poorly differentiated) that has spread and is no longer controlled by radioactive iodine.
- Your cancer has gotten worse within the last 12 months, based on scans.
- You have not had any other treatment for this type of cancer before, aside from radioactive iodine.
- You are 18 years or older and able to swallow pills.
- You are in generally good health (able to do most daily activities) and have adequate organ function (kidneys, liver, bone marrow).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug, XL092, for men with metastatic castration-resistant prostate cancer that has progressed after PSMA-targeted radiation therapy (Lu-177 PSMA-617). It aims to see if the drug can slow down the cancer.
This trial tests a combination of two drugs, XL092 and cemiplimab, for people with a rare and aggressive type of thyroid cancer called anaplastic thyroid cancer. The drugs aim to shrink tumors before surgery and help the immune system fight the cancer.
This trial tests an experimental drug called ST-1898 for people with advanced thyroid cancer that has stopped responding to radioactive iodine treatment and has progressed after at least one targeted therapy. It aims to see if ST-1898 can shrink tumors or slow the disease.
This trial tests a targeted therapy pill (anlotinib) for people with advanced thyroid cancer that stopped responding to radioactive iodine. It may slow tumor growth or shrink tumors.
This study tests a new oral capsule (AL2846) against a placebo in people with advanced thyroid cancer that no longer responds to radioactive iodine. The goal is to see if AL2846 can slow or stop cancer growth.
This trial tests a radioactive drug called 177Lu-LNC1004 for people with a type of thyroid cancer that is no longer responding to standard treatments. The drug targets a protein called FAP found on tumor cells, which may help shrink tumors and slow disease progression.
Hear when a new Locally Advanced Differentiated Thyroid Gland Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.